Susquehanna Fundamental Investments LLC Buys Shares of 50,484 AtriCure, Inc. $ATRC

Susquehanna Fundamental Investments LLC bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 50,484 shares of the medical device company’s stock, valued at approximately $1,413,000.

Several other hedge funds have also made changes to their positions in ATRC. Bank of America Corp DE boosted its position in AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after purchasing an additional 92,830 shares during the period. Assenagon Asset Management S.A. acquired a new stake in AtriCure in the second quarter worth $1,744,000. Rice Hall James & Associates LLC bought a new stake in AtriCure in the second quarter valued at $3,755,000. F m Investments LLC bought a new stake in AtriCure in the fourth quarter valued at $2,872,000. Finally, Vanguard Group Inc. boosted its holdings in shares of AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after acquiring an additional 62,861 shares during the period. Institutional investors own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ATRC. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Piper Sandler raised their price target on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Raymond James Financial set a $52.00 price objective on AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and an average target price of $49.89.

Insider Activity at AtriCure

In other news, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sven Wehrwein sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This represents a 38.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,616 shares of company stock worth $2,149,994 in the last quarter. Company insiders own 4.00% of the company’s stock.

AtriCure Trading Up 1.2%

Shares of NASDAQ:ATRC opened at $48.92 on Wednesday. The company has a 50 day moving average of $38.70 and a 200-day moving average of $32.41. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The firm has a market cap of $2.49 billion, a P/E ratio of 232.96 and a beta of 1.26. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $49.98.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.